Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
about
Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer's Disease.Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease.Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults.The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.Advances in Aβ plaque detection and the value of knowing: overcoming challenges to improving patient outcomes in Alzheimer's disease.Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies.Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study.Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimer's Disease Patients: A Report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL).Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies.The Past and the Future of Alzheimer's Disease Fluid Biomarkers.Automation vs. Experience: Measuring Alzheimer's Beta-Amyloid 1-42 Peptide in the CSF
P2860
Q35855414-468A89BE-786C-4B88-82CD-3B1E1E0B3742Q37627051-11B3C4D6-B887-457C-8519-5C015A89D82BQ38603015-7CADAD43-1110-45F6-B147-1C637254D71FQ38830945-6C0514A2-0392-4837-B275-3BB0C0ACA3A2Q39215443-08882F63-DF71-46C5-AB8A-94E9B8C17DEFQ39451611-42892343-F576-42E4-ABAA-0AA297FF46A8Q46254853-7359B00B-5728-4C19-8EBD-2AD608B703D3Q47145223-DC14EE5C-93C9-4D3B-AF1E-E3CBEE5A92B0Q47794554-7ED14900-855D-4CB5-AF75-555E48FF497AQ51760876-1A8657E6-AC57-4A15-959C-0E84A4E6F0A5Q52644601-9BCE236F-D51A-41C5-A713-9389FA1DC8B1Q58719736-EF6DA9FE-40E8-437D-848C-24C248DE50FC
P2860
Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Alzheimer's Disease Normative ...... rs and Lifestyle (AIBL) study.
@en
type
label
Alzheimer's Disease Normative ...... rs and Lifestyle (AIBL) study.
@en
prefLabel
Alzheimer's Disease Normative ...... rs and Lifestyle (AIBL) study.
@en
P2093
P2860
P921
P356
P1476
Alzheimer's Disease Normative ...... rs and Lifestyle (AIBL) study.
@en
P2093
AIBL Research Group
Alan Rembach
Amelia McGlade
Brendan Silbert
Brett O Trounson
Christopher C Rowe
Christopher J Fowler
David Ames
David Darby
James D Doecke
P2860
P304
P356
10.3233/JAD-150247
P577
2015-08-01T00:00:00Z